R

Ronald Witteles

Alnylam Pharmaceuticals (United States)

ORCID: 0000-0002-3043-1472

271 papers and 14.1k citations.

PubIndex Score97Top 3%How it's scored

271Publications

14.1kTotal Citations

First publication: 1998First senior author: 2007

Top publicationsby citations

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020

Cited by 767

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Marianna Fontana, Mathew S. Maurer, Scott D. Solomon et al.|New England Journal of Medicine|2024

Cited by 356

Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice

Ronald Witteles, Pablo García‐Pavía, Sabahat Bokhari et al.|JACC Heart Failure|2019

Cited by 345

Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> ( <scp>ATTR‐ACT</scp> ) and long‐term extension study

Thibaud Damy, Ronald Witteles, Pablo García‐Pavía et al.|European Journal of Heart Failure|2020

Cited by 207

Indexing the rest of 271 publications…